UK – Evaro, a London, UK-based digital health startup providing AI-powered clinical and drug prescription services for minor conditions, raised $1.5M in Seed funding.
The round was led by Cornerstone VC and Exceptional Ventures, with participation from Catalisi’s investment arm, Syndicate Room and the University of East Anglia. The company intends to use the funds to expand in a B2B market by offering a plug-and-play product that will allow consumer brands to provide managed medication prescription services to their customers. The funding will see Evaro’s medication catalogue grow from 200 to 2,000 treatments, covering 70% of minor health issues typically addressed by NHS doctors. The company also aims to acquire its Care Quality Commission (CQC) licence, enabling more comprehensive patient care, including diagnosis and therapy initiation.Founded in 2018 by Dr. Thuria Wenbar and Dr. Oskar Wendowski, Evaro uses an artificial intelligence and machine learning model trained on 13.5M patient records to provide access to AI-driven asynchronous consultations and private prescription medication. It also uses a stringent regulatory-compliant patient safety process through which online treatment requests require an asynchronous consultation, with mechanisms to detect answer manipulation, and drug orders are scrutinised for safe dosages and quantities, with GP notifications when necessary. 31/01/2024
